Get the Stockscreener App
118.42
3.69%
-4.54
Axsome Therapeutics Inc stock is traded at $118.42, with a volume of 700.70K.
It is down -3.69% in the last 24 hours and up +12.53% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$122.96
Open:
$122.65
24h Volume:
700.70K
Relative Volume:
1.13
Market Cap:
$5.91B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-18.13
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
-5.39%
1M Performance:
+12.53%
6M Performance:
-0.86%
1Y Performance:
+29.07%
1-Day Range:
$117.75
$123.04
1-Week Range:
$117.75
$130.00
52-Week Range:
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
118.42 | 6.19B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Scientech Research LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
Vident Advisory LLC Acquires New Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Adage Capital Partners GP L.L.C. Sells 12,000 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Woodline Partners LP Cuts Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Fred Alger Management LLC Takes $860,000 Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome initiated with Overweight at Wells Fargo on Alzheimer's drug potential - MSN
Axsome Therapeutics (NASDAQ:AXSM) Director Purchases $200,466.00 in Stock - MarketBeat
Axiom Investors LLC DE Invests $3.07 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome therapeutics director Coleman buys $200k+ in shares - Investing.com India
Axsome therapeutics director Coleman buys $200k+ in shares By Investing.com - Investing.com Australia
Axsome Therapeutics, Inc. $AXSM Shares Sold by Cormorant Asset Management LP - MarketBeat
Ieq Capital LLC Takes Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Will Axsome Therapeutics Inc. announce a stock splitJuly 2025 Sector Moves & Low Risk High Win Rate Picks - Lancaster City Council
Axsome Therapeutics at Morgan Stanley: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Axsome Therapeutics at Morgan Stanley: Strategic Growth and Innovation - Investing.com
Sector ETF Data Correlates with Strength in Axsome Therapeutics Inc.2025 Performance Recap & Safe Entry Point Identification - beatles.ru
Roger Jeffs Sells 13,464 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome Therapeutics, Inc. $AXSM is BVF Inc. IL's 2nd Largest Position - MarketBeat
Point72 Europe London LLP Has $1.76 Million Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Russell Investments Group Ltd. Has $308,000 Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
PDT Partners LLC Increases Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
What does recent volatility data suggest for Axsome Therapeutics Inc2025 Key Lessons & Reliable Breakout Forecasts - Newser
What does recent volatility data suggest for Axsome Therapeutics Inc.July 2025 Analyst Calls & Weekly Stock Breakout Alerts - Newser
Axsome therapeutics director Saad sells $1.14 million in shares By Investing.com - Investing.com Australia
Axsome therapeutics director Saad sells $1.14 million in shares - Investing.com
Ranking Axsome Therapeutics Inc. among high performing stocks via toolsQuarterly Profit Review & High Accuracy Buy Signal Tips - Newser
Applying big data sentiment scoring on Axsome Therapeutics Inc.July 2025 PreEarnings & Weekly High Momentum Picks - Newser
Landscape Capital Management L.L.C. Makes New $632,000 Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Published on: 2025-09-05 14:08:02 - Newser
Is Axsome Therapeutics Inc. a stock for growth or value investorsWeekly Profit Recap & High Conviction Buy Zone Picks - خودرو بانک
Best data tools to analyze Axsome Therapeutics Inc. stockTrade Signal Summary & Technical Pattern Alert System - Newser
Using AI based signals to follow Axsome Therapeutics Inc.July 2025 Pullbacks & Weekly High Return Opportunities - Newser
Why Axsome Therapeutics Inc. is moving today2025 Historical Comparison & Smart Investment Allocation Tips - Newser
Custom watchlist performance reports with Axsome Therapeutics Inc.Weekly Investment Report & Fast Entry Momentum Alerts - Newser
Multi asset correlation models including Axsome Therapeutics Inc.Earnings Trend Report & High Conviction Investment Ideas - Newser
Axsome Therapeutics at Cantor Conference: Strategic Growth in Brain Health By Investing.com - Investing.com Canada
Driehaus Capital Management LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Is Axsome Therapeutics Inc.’s growth already priced inCPI Data & Safe Swing Trade Setup Alerts - khodrobank.com
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years - The Globe and Mail
Will Axsome Therapeutics Inc. bounce back from current supportWeekly Gains Summary & High Return Trade Opportunity Guides - Newser
Forecasting Axsome Therapeutics Inc. price range with options dataJuly 2025 Review & Weekly High Potential Alerts - Newser
Wells Fargo Initiates Coverage on Axsome Therapeutics with Overweight Rating and $163 Price Target - AInvest
Relative strength of Axsome Therapeutics Inc. in sector analysisQuarterly Portfolio Review & Long-Term Safe Investment Plans - Newser
Sector ETF performance correlation with Axsome Therapeutics Inc.Volume Spike & Proven Capital Preservation Methods - Newser
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):